Robin Kramer - 09 Mar 2026 Form 4 Insider Report for Armata Pharmaceuticals, Inc. (ARMP)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
11 Mar 2026, 21:18:25 UTC
Prior SEC filing
17 Feb 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Robin Kramer

Key filing fact

Robin Kramer filed Form 4 for Armata Pharmaceuticals, Inc. (ARMP) on 11 Mar 2026.

Key facts

  • This page summarizes Robin Kramer's Form 4 filing for Armata Pharmaceuticals, Inc. (ARMP).
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 11 Mar 2026, 21:18.

Change

  • Previous filing in this sequence was filed on 17 Feb 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001609222 Primary reporting owner

Kramer Robin

Relationship
Director
Address
5005 MCCONNELL AVENUE, LOS ANGELES
Signature
/s/ Robin Kramer
Signature date
11 Mar 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ARMP transaction Derivative

Stock Options (Right to Buy)

Award

Transaction value
Shares
+25,640
Change %
Price
$0.000000*
Shares after
25,640
Date
09 Mar 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
25,640
Exercise price
$11.61
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The Stock Options will vest in full on March 9, 2027, subject to continuous service through the vesting date.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .